Guerbet has announced that it has signed an agreement to acquire a laboratory-stage technology developed by Occlugel, a French company specialised in the research and development of microspheres used in embolization.
This acquisition is line with the GEAR 2023 strategic plan, and is one of two acquisitions planned by the end of this financial year.
“We are very pleased to integrate this new microsphere technology into our Interventional Imaging research and development programme”, said Claire Corot, Research, Innovation & Business Development vice president.
Under the terms of the agreement and in exchange for the acquisition of this technology, Guerbet has made an initial payment of €3 million, with additional payments conditional on completing the technology transfer and achieving regulatory objectives.
A complementary technology to interventional imaging
The technology will be used in several ranges of microspheres for vascular embolization of benign tumours, for example uterine fibroma and prostate adenoma, and for vascular chemoembolization of malignant tumours, including in some liver, lung and kidney cancers.
This technology will complete the existing range of Guerbet’s Interventional Imaging solutions, and above all create strong synergies with the Accurate range of antireflux microcatheters, acquired recently by Guerbet.